drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00792 | DB01202 | 832 | 1,435 | [
"DDInter1878",
"DDInter1046"
] | Tripelennamine | Levetiracetam | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
832,
24,
1435
]
],
[
[
832,
63,
701
],
[
701,
24,
1435
]
],
[
[
832,
24,
1376
],
[
1376,
24,
1435
]
],
[
[
832,
35,
272
],
[
272,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydr... |
DB08899 | DB11986 | 129 | 484 | [
"DDInter649",
"DDInter648"
] | Enzalutamide | Entrectinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
129,
25,
484
]
],
[
[
129,
62,
1247
],
[
1247,
23,
484
]
],
[
[
129,
25,
466
],
[
466,
62,
484
]
],
[
[
129,
25,
1135
],
[
1135,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolu... |
DB00831 | DB01156 | 1,178 | 593 | [
"DDInter1866",
"DDInter252"
] | Trifluoperazine | Bupropion | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1178,
25,
593
]
],
[
[
1178,
6,
7950
],
[
7950,
45,
593
]
],
[
[
1178,
18,
4798
],
[
4798,
57,
593
]
],
[
[
1178,
7,
2271
],
[
2271,
... | [
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Trifluoperazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Bupropion (Compound)
Trifluoperazine (Compound) downregulates GNAS (Gene) and GNAS (Gene) is downregulated by Bupropion (Compound)
Trifluoperazine (Compound) upregulates STXBP1 (Gene) and STXBP1 (Gene) is downregulated by Bupropion (Compound)
... |
DB00562 | DB11126 | 1,014 | 900 | [
"DDInter188",
"DDInter276"
] | Benzthiazide | Calcium gluconate | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1014,
24,
900
]
],
[
[
1014,
40,
674
],
[
674,
24,
900
]
],
[
[
1014,
23,
1669
],
[
1669,
24,
900
]
],
[
[
1014,
1,
323
],
[
323,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
... | Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline may cause a mode... |
DB00348 | DB00472 | 254 | 758 | [
"DDInter1300",
"DDInter758"
] | Nitisinone | Fluoxetine | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
254,
24,
758
]
],
[
[
254,
21,
29097
],
[
29097,
60,
758
]
],
[
[
254,
24,
1250
],
[
1250,
63,
758
]
],
[
[
254,
63,
600
],
[
600,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is caused... | Nitisinone (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Fluoxetine (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
... |
DB00030 | DB00059 | 1,685 | 1,560 | [
"DDInter934",
"DDInter1404"
] | Insulin human | Pegaspargase | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moderate | 1 | [
[
[
1685,
24,
1560
]
],
[
[
1685,
24,
1021
],
[
1021,
63,
1560
]
],
[
[
1685,
25,
1299
],
[
1299,
63,
1560
]
],
[
[
1685,
24,
695
],
[
695... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Insulin human may lead to a major life threatening interaction when taken with Trovafloxacin and Trovaflo... |
DB01136 | DB01168 | 772 | 1,053 | [
"DDInter305",
"DDInter1526"
] | Carvedilol | Procarbazine | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
772,
24,
1053
]
],
[
[
772,
63,
848
],
[
848,
40,
1053
]
],
[
[
772,
6,
16392
],
[
16392,
45,
1053
]
],
[
[
772,
21,
28762
],
[
28762,... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Carvedilol (Compound) binds XDH (Gene) and XDH (Gene) is bound by Procarbazine (Compound)
Carvedilol (Compound) causes Headache (Side Effect) and Headache (Side... |
DB00405 | DB00490 | 128 | 946 | [
"DDInter517",
"DDInter254"
] | Dexbrompheniramine | Buspirone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Moderate | 1 | [
[
[
128,
24,
946
]
],
[
[
128,
63,
1242
],
[
1242,
24,
946
]
],
[
[
128,
24,
820
],
[
820,
63,
946
]
],
[
[
128,
24,
1233
],
[
1233,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimem... |
DB08934 | DB11718 | 1,200 | 927 | [
"DDInter1695",
"DDInter640"
] | Sofosbuvir | Encorafenib | Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 bein... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1200,
24,
927
]
],
[
[
1200,
25,
1017
],
[
1017,
64,
927
]
],
[
[
1200,
64,
129
],
[
129,
25,
927
]
],
[
[
1200,
25,
1017
],
[
1017,
... | [
[
[
"Sofosbuvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Sofosbuvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatini... | Sofosbuvir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib
Sofosbuvir may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatenin... |
DB06228 | DB08886 | 792 | 637 | [
"DDInter1609",
"DDInter126"
] | Rivaroxaban | Asparaginase Erwinia chrysanthemi | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
792,
24,
637
]
],
[
[
792,
63,
392
],
[
392,
24,
637
]
],
[
[
792,
64,
1479
],
[
1479,
24,
637
]
],
[
[
792,
25,
936
],
[
936,
2... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"La... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Rivaroxaban may lead to a major life threatening interaction when taken with Acetylsalicyl... |
DB00489 | DB00501 | 17 | 752 | [
"DDInter1704",
"DDInter380"
] | Sotalol | Cimetidine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
17,
24,
752
]
],
[
[
17,
21,
29134
],
[
29134,
60,
752
]
],
[
[
17,
23,
112
],
[
112,
62,
752
]
],
[
[
17,
62,
542
],
[
542,
23,... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Flatulence"
],
[
"Flatulence",
"{u} (Side Effect) is caused b... | Sotalol (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidin... |
DB01097 | DB05812 | 1,377 | 1,374 | [
"DDInter1033",
"DDInter8"
] | Leflunomide | Abiraterone | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
1377,
25,
1374
]
],
[
[
1377,
64,
1561
],
[
1561,
1,
1374
]
],
[
[
1377,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1377,
63,
112
],
[
11... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Testosterone"
],
[
"Testosterone",
... | Leflunomide may lead to a major life threatening interaction when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Leflunomide (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Leflunomide may cause a moderate interaction ... |
DB00250 | DB00773 | 10 | 896 | [
"DDInter475",
"DDInter702"
] | Dapsone | Etoposide | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
10,
24,
896
]
],
[
[
10,
6,
7524
],
[
7524,
45,
896
]
],
[
[
10,
21,
29547
],
[
29547,
60,
896
]
],
[
[
10,
23,
307
],
[
307,
23... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound)
Dapsone (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Etoposide (Compound)
Dapsone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Moda... |
DB00193 | DB06616 | 534 | 594 | [
"DDInter1841",
"DDInter224"
] | Tramadol | Bosutinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
534,
24,
594
]
],
[
[
534,
6,
8374
],
[
8374,
45,
594
]
],
[
[
534,
18,
20113
],
[
20113,
57,
594
]
],
[
[
534,
21,
29231
],
[
29231,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Tramadol (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Bosutinib (Compound)
Tramadol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)... |
DB00191 | DB06262 | 73 | 1,354 | [
"DDInter1447",
"DDInter606"
] | Phentermine | Droxidopa | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Moderate | 1 | [
[
[
73,
24,
1354
]
],
[
[
73,
24,
874
],
[
874,
24,
1354
]
],
[
[
73,
24,
584
],
[
584,
40,
1354
]
],
[
[
73,
6,
7390
],
[
7390,
45,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin and ... |
DB00019 | DB04865 | 1,257 | 4 | [
"DDInter1405",
"DDInter1335"
] | Pegfilgrastim | Omacetaxine mepesuccinate | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1257,
24,
4
]
],
[
[
1257,
24,
1394
],
[
1394,
24,
4
]
],
[
[
1257,
24,
631
],
[
631,
63,
4
]
],
[
[
1257,
63,
491
],
[
491,
24,... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rituxi... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ta... |
DB00467 | DB01234 | 1,467 | 1,220 | [
"DDInter644",
"DDInter513"
] | Enoxacin | Dexamethasone | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
1467,
25,
1220
]
],
[
[
1467,
25,
870
],
[
870,
1,
1220
]
],
[
[
1467,
25,
175
],
[
175,
40,
1220
]
],
[
[
1467,
64,
251
],
[
251,
... | [
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
... | Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Enoxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Enoxacin may... |
DB00163 | DB01042 | 1,461 | 1,307 | [
"DDInter1943",
"DDInter1144"
] | Vitamin E | Melphalan | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
1461,
24,
1307
]
],
[
[
1461,
24,
168
],
[
168,
23,
1307
]
],
[
[
1461,
62,
66
],
[
66,
24,
1307
]
],
[
[
1461,
23,
1683
],
[
1683,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab ma... |
DB00748 | DB09272 | 662 | 412 | [
"DDInter297",
"DDInter632"
] | Carbinoxamine | Eluxadoline | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
662,
24,
412
]
],
[
[
662,
63,
1594
],
[
1594,
24,
412
]
],
[
[
662,
24,
543
],
[
543,
24,
412
]
],
[
[
662,
35,
849
],
[
849,
2... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and... |
DB00004 | DB15091 | 669 | 676 | [
"DDInter499",
"DDInter1901"
] | Denileukin diftitox | Upadacitinib | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
669,
25,
676
]
],
[
[
669,
24,
1430
],
[
1430,
24,
676
]
],
[
[
669,
24,
1184
],
[
1184,
25,
676
]
],
[
[
669,
25,
1064
],
[
1064,
... | [
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00647 | DB01166 | 675 | 477 | [
"DDInter528",
"DDInter379"
] | Dextropropoxyphene | Cilostazol | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
675,
24,
477
]
],
[
[
675,
6,
8374
],
[
8374,
45,
477
]
],
[
[
675,
7,
5202
],
[
5202,
46,
477
]
],
[
[
675,
21,
28892
],
[
28892,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by ... | Dextropropoxyphene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Dextropropoxyphene (Compound) upregulates HP (Gene) and HP (Gene) is upregulated by Cilostazol (Compound)
Dextropropoxyphene (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by ... |
DB06228 | DB08901 | 792 | 1,468 | [
"DDInter1609",
"DDInter1492"
] | Rivaroxaban | Ponatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
792,
25,
1468
]
],
[
[
792,
63,
478
],
[
478,
24,
1468
]
],
[
[
792,
6,
7524
],
[
7524,
45,
1468
]
],
[
[
792,
21,
29425
],
[
29425,
... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib"... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rivaroxaban (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ponatinib (Compound)
Rivaroxaban (Compoun... |
DB00361 | DB12332 | 134 | 1,619 | [
"DDInter1939",
"DDInter1626"
] | Vinorelbine | Rucaparib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
134,
24,
1619
]
],
[
[
134,
23,
307
],
[
307,
23,
1619
]
],
[
[
134,
24,
112
],
[
112,
23,
1619
]
],
[
[
134,
24,
259
],
[
259,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronid... |
DB00907 | DB01577 | 290 | 1,529 | [
"DDInter427",
"DDInter1161"
] | Cocaine (topical) | Metamfetamine | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Major | 2 | [
[
[
290,
25,
1529
]
],
[
[
290,
64,
939
],
[
939,
40,
1529
]
],
[
[
290,
25,
1161
],
[
1161,
40,
1529
]
],
[
[
290,
25,
93
],
[
93,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u... | Cocaine may lead to a major life threatening interaction when taken with Metamfetamine
Cocaine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Cocaine may lead to a major life threatening interaction when taken with Selegilin... |
DB01253 | DB06791 | 628 | 1,446 | [
"DDInter664",
"DDInter1021"
] | Ergometrine | Lanreotide | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
628,
24,
1446
]
],
[
[
628,
1,
469
],
[
469,
24,
1446
]
],
[
[
628,
24,
1017
],
[
1017,
63,
1446
]
],
[
[
628,
1,
469
],
[
469,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Ergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may cause a... | Ergometrine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction th... |
DB01082 | DB09156 | 1,448 | 777 | [
"DDInter1713",
"DDInter964"
] | Streptomycin | Iopromide | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
1448,
25,
777
]
],
[
[
1448,
64,
1028
],
[
1028,
24,
777
]
],
[
[
1448,
24,
242
],
[
242,
63,
777
]
],
[
[
1448,
63,
372
],
[
372,
... | [
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u... | Streptomycin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cau... |
DB01377 | DB06626 | 1,283 | 263 | [
"DDInter1119",
"DDInter147"
] | Magnesium oxide | Axitinib | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Minor | 0 | [
[
[
1283,
23,
263
]
],
[
[
1283,
62,
752
],
[
752,
23,
263
]
],
[
[
1283,
24,
460
],
[
460,
62,
263
]
],
[
[
1283,
24,
1250
],
[
1250,
... | [
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbona... |
DB00078 | DB00991 | 1,172 | 97 | [
"DDInter898",
"DDInter1358"
] | Ibritumomab tiuxetan | Oxaprozin | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Major | 2 | [
[
[
1172,
25,
97
]
],
[
[
1172,
37,
1274
],
[
1274,
24,
97
]
],
[
[
1172,
25,
998
],
[
998,
1,
97
]
],
[
[
1172,
25,
936
],
[
936,
6... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxapro... |
DB01309 | DB01611 | 1,254 | 1,487 | [
"DDInter933",
"DDInter893"
] | Insulin glulisine | Hydroxychloroquine | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1254,
24,
1487
]
],
[
[
1254,
63,
1247
],
[
1247,
23,
1487
]
],
[
[
1254,
63,
168
],
[
168,
24,
1487
]
],
[
[
1254,
24,
1060
],
[
1060... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfa... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when ... |
DB01004 | DB11703 | 563 | 405 | [
"DDInter806",
"DDInter9"
] | Ganciclovir | Acalabrutinib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
563,
24,
405
]
],
[
[
563,
63,
1101
],
[
1101,
24,
405
]
],
[
[
563,
1,
248
],
[
248,
24,
405
]
],
[
[
563,
24,
951
],
[
951,
24... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may cause a moderate interact... |
DB00112 | DB11866 | 374 | 1,068 | [
"DDInter201",
"DDInter1618"
] | Bevacizumab | Romosozumab | There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its at... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
374,
24,
1068
]
],
[
[
374,
25,
770
],
[
770,
24,
1068
]
],
[
[
374,
25,
770
],
[
770,
24,
1069
],
[
1069,
24,
1068
]
],
[
[
374,
... | [
[
[
"Bevacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Bevacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalid... | Bevacizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Bevacizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a modera... |
DB00285 | DB09030 | 1,100 | 840 | [
"DDInter1927",
"DDInter1945"
] | Venlafaxine | Vorapaxar | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
1100,
24,
840
]
],
[
[
1100,
24,
885
],
[
885,
24,
840
]
],
[
[
1100,
24,
1017
],
[
1017,
63,
840
]
],
[
[
1100,
25,
1039
],
[
1039,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and L... |
DB00877 | DB09134 | 629 | 1,552 | [
"DDInter1678",
"DDInter966"
] | Sirolimus | Ioversol | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
629,
25,
1552
]
],
[
[
629,
24,
33
],
[
33,
24,
1552
]
],
[
[
629,
63,
228
],
[
228,
24,
1552
]
],
[
[
629,
24,
242
],
[
242,
63... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dofetilide and Dofetilide... |
DB00443 | DB10429 | 251 | 200 | [
"DDInter195",
"DDInter282"
] | Betamethasone | Candida albicans | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
251,
24,
200
]
],
[
[
251,
24,
1683
],
[
1683,
24,
200
]
],
[
[
251,
25,
976
],
[
976,
24,
200
]
],
[
[
251,
1,
1486
],
[
1486,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Betamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofaci... |
DB00252 | DB01259 | 362 | 392 | [
"DDInter1460",
"DDInter1024"
] | Phenytoin | Lapatinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
362,
24,
392
]
],
[
[
362,
6,
4973
],
[
4973,
45,
392
]
],
[
[
362,
21,
28688
],
[
28688,
60,
392
]
],
[
[
362,
25,
1135
],
[
1135,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Phenytoin (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Lapatinib (Compound)
Phenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor... |
DB00215 | DB00377 | 1,230 | 1,494 | [
"DDInter388",
"DDInter1382"
] | Citalopram | Palonosetron | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Major | 2 | [
[
[
1230,
25,
1494
]
],
[
[
1230,
6,
12523
],
[
12523,
45,
1494
]
],
[
[
1230,
21,
28723
],
[
28723,
60,
1494
]
],
[
[
1230,
23,
112
],
[
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Palon... | Citalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Palonosetron (Compound)
Citalopram (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Palonosetron (Compound)
Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB00405 | DB11632 | 128 | 580 | [
"DDInter517",
"DDInter1343"
] | Dexbrompheniramine | Opicapone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
128,
24,
580
]
],
[
[
128,
24,
104
],
[
104,
24,
580
]
],
[
[
128,
63,
999
],
[
999,
24,
580
]
],
[
[
128,
74,
1594
],
[
1594,
2... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Th... |
DB01611 | DB08875 | 1,487 | 1,618 | [
"DDInter893",
"DDInter262"
] | Hydroxychloroquine | Cabozantinib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1487,
25,
1618
]
],
[
[
1487,
63,
112
],
[
112,
23,
1618
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
1618
]
],
[
[
1487,
63,
723
],
[
723,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with S... |
DB01165 | DB06292 | 1,539 | 549 | [
"DDInter1325",
"DDInter474"
] | Ofloxacin | Dapagliflozin | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1539,
24,
549
]
],
[
[
1539,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1539,
6,
7950
],
[
7950,
45,
549
]
],
[
[
1539,
21,
29222
],
[
29222... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Ofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dapagliflozin (Compound)
Ofloxacin (Compound) causes Hypoglycaemia (Side Effect) ... |
DB00794 | DB06772 | 759 | 310 | [
"DDInter1521",
"DDInter259"
] | Primidone | Cabazitaxel | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
759,
24,
310
]
],
[
[
759,
24,
973
],
[
973,
24,
310
]
],
[
[
759,
6,
3486
],
[
3486,
45,
310
]
],
[
[
759,
21,
28692
],
[
28692,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Primidone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Primidone (Compoun... |
DB00726 | DB09065 | 1,164 | 760 | [
"DDInter1876",
"DDInter424"
] | Trimipramine | Cobicistat | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1164,
24,
760
]
],
[
[
1164,
24,
1374
],
[
1374,
23,
760
]
],
[
[
1164,
25,
868
],
[
868,
24,
760
]
],
[
[
1164,
24,
609
],
[
609,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Trimipramine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may ... |
DB00543 | DB04868 | 87 | 478 | [
"DDInter82",
"DDInter1293"
] | Amoxapine | Nilotinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
87,
25,
478
]
],
[
[
87,
6,
12523
],
[
12523,
45,
478
]
],
[
[
87,
7,
5509
],
[
5509,
57,
478
]
],
[
[
87,
21,
28762
],
[
28762,
... | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Amoxapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"... | Amoxapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nilotinib (Compound)
Amoxapine (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is downregulated by Nilotinib (Compound)
Amoxapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Amoxapine ma... |
DB09330 | DB13879 | 985 | 1,043 | [
"DDInter1352",
"DDInter824"
] | Osimertinib | Glecaprevir | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
985,
24,
1043
]
],
[
[
985,
63,
353
],
[
353,
24,
1043
]
],
[
[
985,
24,
466
],
[
466,
24,
1043
]
],
[
[
985,
64,
594
],
[
594,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide a... |
DB06228 | DB09065 | 792 | 760 | [
"DDInter1609",
"DDInter424"
] | Rivaroxaban | Cobicistat | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
792,
25,
760
]
],
[
[
792,
63,
1230
],
[
1230,
23,
760
]
],
[
[
792,
24,
555
],
[
555,
23,
760
]
],
[
[
792,
24,
875
],
[
875,
2... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopr... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupi... |
DB01036 | DB11986 | 211 | 484 | [
"DDInter1832",
"DDInter648"
] | Tolterodine | Entrectinib | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
211,
24,
484
]
],
[
[
211,
24,
1478
],
[
1478,
24,
484
]
],
[
[
211,
24,
159
],
[
159,
63,
484
]
],
[
[
211,
62,
883
],
[
883,
2... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB01227 | DB12245 | 1,301 | 823 | [
"DDInter1043",
"DDInter1863"
] | Levacetylmethadol | Triclabendazole | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
1301,
25,
823
]
],
[
[
1301,
62,
112
],
[
112,
23,
823
]
],
[
[
1301,
64,
1010
],
[
1010,
24,
823
]
],
[
[
1301,
24,
28
],
[
28,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Levacetylmethadol may lead to a major life threatening interaction when taken with Mefloquine and ... |
DB06589 | DB06643 | 1,250 | 1,136 | [
"DDInter1400",
"DDInter500"
] | Pazopanib | Denosumab | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1250,
24,
1136
]
],
[
[
1250,
63,
1213
],
[
1213,
24,
1136
]
],
[
[
1250,
64,
1377
],
[
1377,
24,
1136
]
],
[
[
1250,
25,
39
],
[
39,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Pazopanib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a m... |
DB00254 | DB06723 | 964 | 115 | [
"DDInter598",
"DDInter58"
] | Doxycycline | Aluminum hydroxide | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
964,
24,
115
]
],
[
[
964,
24,
1482
],
[
1482,
23,
115
]
],
[
[
964,
24,
339
],
[
339,
24,
115
]
],
[
[
964,
24,
428
],
[
428,
6... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Bacampicillin a... |
DB00519 | DB01050 | 1,638 | 848 | [
"DDInter1843",
"DDInter900"
] | Trandolapril | Ibuprofen | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1638,
24,
848
]
],
[
[
1638,
24,
1053
],
[
1053,
1,
848
]
],
[
[
1638,
21,
28773
],
[
28773,
60,
848
]
],
[
[
1638,
23,
286
],
[
286,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Trandolapril (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Ibuprofen (Compound)
Trandolapril may cause... |
DB00092 | DB00717 | 58 | 1,197 | [
"DDInter40",
"DDInter1312"
] | Alefacept | Norethisterone | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Moderate | 1 | [
[
[
58,
24,
1197
]
],
[
[
58,
24,
890
],
[
890,
1,
1197
]
],
[
[
58,
24,
566
],
[
566,
40,
1197
]
],
[
[
58,
24,
259
],
[
259,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Norethisterone (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Norethisterone... |
DB01159 | DB08881 | 419 | 868 | [
"DDInter854",
"DDInter1925"
] | Halothane | Vemurafenib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
419,
25,
868
]
],
[
[
419,
6,
8374
],
[
8374,
45,
868
]
],
[
[
419,
62,
112
],
[
112,
23,
868
]
],
[
[
419,
63,
480
],
[
480,
24... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafe... | Halothane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Halothane may ca... |
DB00322 | DB01165 | 141 | 1,539 | [
"DDInter742",
"DDInter1325"
] | Floxuridine | Ofloxacin | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
141,
23,
1539
]
],
[
[
141,
23,
1467
],
[
1467,
1,
1539
]
],
[
[
141,
62,
1176
],
[
1176,
1,
1539
]
],
[
[
141,
23,
945
],
[
945,
... | [
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"... | Floxuridine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Flox... |
DB00047 | DB00359 | 176 | 161 | [
"DDInter932",
"DDInter1721"
] | Insulin glargine | Sulfadiazine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Moderate | 1 | [
[
[
176,
24,
161
]
],
[
[
176,
24,
1029
],
[
1029,
40,
161
]
],
[
[
176,
24,
1560
],
[
1560,
24,
161
]
],
[
[
176,
24,
959
],
[
959,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadiazine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfadiazine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderat... |
DB00798 | DB01276 | 1,132 | 123 | [
"DDInter815",
"DDInter706"
] | Gentamicin | Exenatide | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1132,
24,
123
]
],
[
[
1132,
62,
1252
],
[
1252,
23,
123
]
],
[
[
1132,
24,
1338
],
[
1338,
24,
123
]
],
[
[
1132,
24,
445
],
[
445,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Gentamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"D... | Gentamicin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenam... |
DB04845 | DB08881 | 309 | 868 | [
"DDInter1001",
"DDInter1925"
] | Ixabepilone | Vemurafenib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
309,
24,
868
]
],
[
[
309,
6,
8374
],
[
8374,
45,
868
]
],
[
[
309,
6,
5816
],
[
5816,
57,
868
]
],
[
[
309,
21,
28847
],
[
28847,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Ixabepilone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Ixabepilone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ixabepilone (Compound) binds TUBB4B (Gene) and TUBB4B (Gene) is downregulated by Vemurafenib (Compound)
Ixabepilone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compou... |
DB00313 | DB00427 | 556 | 1,233 | [
"DDInter1913",
"DDInter1879"
] | Valproic acid | Triprolidine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
556,
24,
1233
]
],
[
[
556,
24,
104
],
[
104,
63,
1233
]
],
[
[
556,
24,
1242
],
[
1242,
24,
1233
]
],
[
[
556,
63,
701
],
[
701,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cetirizin... |
DB00529 | DB01611 | 789 | 1,487 | [
"DDInter779",
"DDInter893"
] | Foscarnet | Hydroxychloroquine | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
789,
25,
1487
]
],
[
[
789,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
789,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
789,
24,
286
],
[
286,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Prim... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Foscarnet (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)... |
DB03404 | DB11166 | 765 | 18 | [
"DDInter855",
"DDInter104"
] | Hemin | Antithrombin Alfa | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
765,
24,
18
]
],
[
[
765,
63,
714
],
[
714,
24,
18
]
],
[
[
765,
24,
1496
],
[
1496,
24,
18
]
],
[
[
765,
63,
1172
],
[
1172,
25... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"... | Hemin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib ma... |
DB01610 | DB06772 | 248 | 310 | [
"DDInter1912",
"DDInter259"
] | Valganciclovir | Cabazitaxel | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
248,
24,
310
]
],
[
[
248,
63,
973
],
[
973,
24,
310
]
],
[
[
248,
21,
28692
],
[
28692,
60,
310
]
],
[
[
248,
24,
351
],
[
351,
... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],... | Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Valganciclovir (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused ... |
DB00191 | DB01037 | 73 | 1,161 | [
"DDInter1447",
"DDInter1653"
] | Phentermine | Selegiline | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Major | 2 | [
[
[
73,
36,
1161
]
],
[
[
73,
25,
551
],
[
551,
1,
1161
]
],
[
[
73,
36,
1529
],
[
1529,
1,
1161
]
],
[
[
73,
40,
11284
],
[
11284,
... | [
[
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"... | Phentermine (Compound) resembles Selegiline (Compound) and
Phentermine may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Phentermine (Compound) resembles Metamfetamine (Compound) and Phentermine may lead to a major life threatening inte... |
DB01229 | DB06674 | 973 | 908 | [
"DDInter1377",
"DDInter837"
] | Paclitaxel | Golimumab | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
973,
25,
908
]
],
[
[
973,
63,
1461
],
[
1461,
23,
908
]
],
[
[
973,
63,
336
],
[
336,
24,
908
]
],
[
[
973,
24,
651
],
[
651,
2... | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine ... |
DB04948 | DB11901 | 1,084 | 913 | [
"DDInter1083",
"DDInter107"
] | Lofexidine | Apalutamide | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1084,
24,
913
]
],
[
[
1084,
62,
112
],
[
112,
23,
913
]
],
[
[
1084,
63,
600
],
[
600,
24,
913
]
],
[
[
1084,
24,
28
],
[
28,
2... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB01259 | DB09074 | 392 | 1,362 | [
"DDInter1024",
"DDInter1327"
] | Lapatinib | Olaparib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
392,
24,
1362
]
],
[
[
392,
24,
627
],
[
627,
63,
1362
]
],
[
[
392,
63,
896
],
[
896,
24,
1362
]
],
[
[
392,
64,
576
],
[
576,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir and Bictegravir may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide... |
DB00095 | DB12159 | 66 | 12 | [
"DDInter623",
"DDInter609"
] | Efalizumab | Dupilumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Moderate | 1 | [
[
[
66,
24,
12
]
],
[
[
66,
23,
1461
],
[
1461,
23,
12
]
],
[
[
66,
63,
599
],
[
599,
24,
12
]
],
[
[
66,
24,
1136
],
[
1136,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab ... |
DB00238 | DB09082 | 188 | 659 | [
"DDInter1285",
"DDInter1934"
] | Nevirapine | Vilanterol | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
188,
24,
659
]
],
[
[
188,
24,
1220
],
[
1220,
23,
659
]
],
[
[
188,
24,
927
],
[
927,
63,
659
]
],
[
[
188,
24,
1069
],
[
1069,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and E... |
DB00726 | DB08881 | 1,164 | 868 | [
"DDInter1876",
"DDInter1925"
] | Trimipramine | Vemurafenib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1164,
25,
868
]
],
[
[
1164,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1164,
7,
4634
],
[
4634,
46,
868
]
],
[
[
1164,
7,
6886
],
[
6886,
... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ve... | Trimipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Trimipramine (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Vemurafenib (Compound)
Trimipramine (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound)
Trimipr... |
DB00280 | DB00427 | 494 | 1,233 | [
"DDInter575",
"DDInter1879"
] | Disopyramide | Triprolidine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
494,
24,
1233
]
],
[
[
494,
24,
262
],
[
262,
63,
1233
]
],
[
[
494,
1,
573
],
[
573,
63,
1233
]
],
[
[
494,
40,
576
],
[
576,
2... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Disopyramide (Compound) resembles Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction th... |
DB00640 | DB01211 | 1,585 | 609 | [
"DDInter31",
"DDInter393"
] | Adenosine | Clarithromycin | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1585,
24,
609
]
],
[
[
1585,
18,
2183
],
[
2183,
57,
609
]
],
[
[
1585,
21,
28662
],
[
28662,
60,
609
]
],
[
[
1585,
63,
600
],
[
600,... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by ... | Adenosine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Clarithromycin (Compound)
Adenosine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Flucon... |
DB00261 | DB11932 | 702 | 327 | [
"DDInter93",
"DDInter3"
] | Anagrelide | Abametapir (topical) | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
702,
24,
327
]
],
[
[
702,
25,
124
],
[
124,
63,
327
]
],
[
[
702,
63,
168
],
[
168,
24,
327
]
],
[
[
702,
25,
292
],
[
292,
24,... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Anagrelide may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Anagrelide may cause a mode... |
DB09046 | DB11689 | 1,094 | 321 | [
"DDInter1201",
"DDInter1659"
] | Metreleptin | Selumetinib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
1094,
24,
321
]
],
[
[
1094,
24,
1297
],
[
1297,
63,
321
]
],
[
[
1094,
63,
578
],
[
578,
24,
321
]
],
[
[
1094,
24,
951
],
[
951,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and... |
DB01075 | DB06204 | 1,376 | 768 | [
"DDInter569",
"DDInter1746"
] | Diphenhydramine | Tapentadol | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
1376,
24,
768
]
],
[
[
1376,
6,
10215
],
[
10215,
45,
768
]
],
[
[
1376,
21,
28921
],
[
28921,
60,
768
]
],
[
[
1376,
63,
1123
],
[
11... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} ... | Diphenhydramine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound)
Diphenhydramine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tapentadol (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Pr... |
DB00595 | DB00728 | 1,545 | 1,610 | [
"DDInter1374",
"DDInter1612"
] | Oxytetracycline | Rocuronium | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Moderate | 1 | [
[
[
1545,
24,
1610
]
],
[
[
1545,
24,
728
],
[
728,
40,
1610
]
],
[
[
1545,
40,
964
],
[
964,
24,
1610
]
],
[
[
1545,
24,
544
],
[
544,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Oxytetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01088 | DB01138 | 714 | 804 | [
"DDInter908",
"DDInter1726"
] | Iloprost | Sulfinpyrazone | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
714,
24,
804
]
],
[
[
714,
63,
998
],
[
998,
1,
804
]
],
[
[
714,
63,
582
],
[
582,
24,
804
]
],
[
[
714,
24,
557
],
[
557,
63,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may cause a moderate interaction that... |
DB00197 | DB00570 | 1,324 | 147 | [
"DDInter1881",
"DDInter1936"
] | Troglitazone | Vinblastine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
1324,
24,
147
]
],
[
[
1324,
25,
246
],
[
246,
62,
147
]
],
[
[
1324,
24,
1539
],
[
1539,
62,
147
]
],
[
[
1324,
24,
1176
],
[
1176,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gat... | Troglitazone may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may c... |
DB01098 | DB09154 | 14 | 1,475 | [
"DDInter1622",
"DDInter1686"
] | Rosuvastatin | Sodium citrate | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
14,
24,
1475
]
],
[
[
14,
24,
1468
],
[
1468,
23,
1475
]
],
[
[
14,
63,
954
],
[
954,
23,
1475
]
],
[
[
14,
24,
1406
],
[
1406,
... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Qui... |
DB00624 | DB12267 | 1,561 | 1,476 | [
"DDInter1775",
"DDInter233"
] | Testosterone | Brigatinib | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1561,
24,
1476
]
],
[
[
1561,
24,
629
],
[
629,
24,
1476
]
],
[
[
1561,
63,
176
],
[
176,
24,
1476
]
],
[
[
1561,
25,
1250
],
[
1250,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine an... |
DB00222 | DB00603 | 245 | 303 | [
"DDInter825",
"DDInter1137"
] | Glimepiride | Medroxyprogesterone acetate | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
245,
24,
303
]
],
[
[
245,
24,
167
],
[
167,
1,
303
]
],
[
[
245,
24,
1561
],
[
1561,
40,
303
]
],
[
[
245,
6,
6017
],
[
6017,
4... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocor... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) r... |
DB00776 | DB11730 | 1,335 | 351 | [
"DDInter1360",
"DDInter1588"
] | Oxcarbazepine | Ribociclib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1335,
24,
351
]
],
[
[
1335,
24,
466
],
[
466,
62,
351
]
],
[
[
1335,
24,
222
],
[
222,
23,
351
]
],
[
[
1335,
24,
310
],
[
310,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine a... |
DB01221 | DB06764 | 1,190 | 1,090 | [
"DDInter1007",
"DDInter1788"
] | Ketamine | Tetryzoline (ophthalmic) | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1190,
24,
1090
]
],
[
[
1190,
24,
144
],
[
144,
63,
1090
]
],
[
[
1190,
63,
1148
],
[
1148,
24,
1090
]
],
[
[
1190,
24,
1629
],
[
1629... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Ketamine may... |
DB03619 | DB09075 | 557 | 498 | [
"DDInter501",
"DDInter621"
] | Deoxycholic acid | Edoxaban | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
557,
24,
498
]
],
[
[
557,
24,
1496
],
[
1496,
63,
498
]
],
[
[
557,
63,
582
],
[
582,
25,
498
]
],
[
[
557,
24,
397
],
[
397,
2... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Reteplase a... |
DB00226 | DB06691 | 1,000 | 849 | [
"DDInter845",
"DDInter1155"
] | Guanadrel | Mepyramine | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1000,
24,
849
]
],
[
[
1000,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1000,
24,
1376
],
[
1376,
24,
849
]
],
[
[
1000,
25,
1214
],
[
1214,... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and D... |
DB11901 | DB14509 | 913 | 1,399 | [
"DDInter107",
"DDInter1081"
] | Apalutamide | Lithium carbonate | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
913,
24,
1399
]
],
[
[
913,
64,
1374
],
[
1374,
24,
1399
]
],
[
[
913,
63,
820
],
[
820,
24,
1399
]
],
[
[
913,
25,
484
],
[
484,
... | [
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"... | Apalutamide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazi... |
DB01255 | DB05294 | 633 | 1,069 | [
"DDInter1078",
"DDInter1917"
] | Lisdexamfetamine | Vandetanib | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
633,
25,
1069
]
],
[
[
633,
21,
28883
],
[
28883,
60,
1069
]
],
[
[
633,
62,
112
],
[
112,
23,
1069
]
],
[
[
633,
24,
659
],
[
659,
... | [
[
[
"Lisdexamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is... | Lisdexamfetamine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Vandetanib (Compound)
Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects w... |
DB00524 | DB09082 | 811 | 659 | [
"DDInter1199",
"DDInter1934"
] | Metolazone | Vilanterol | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
811,
24,
659
]
],
[
[
811,
24,
1220
],
[
1220,
23,
659
]
],
[
[
811,
63,
251
],
[
251,
23,
659
]
],
[
[
811,
24,
1296
],
[
1296,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and... |
DB00852 | DB00938 | 1,445 | 455 | [
"DDInter1545",
"DDInter1635"
] | Pseudoephedrine | Salmeterol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1445,
24,
455
]
],
[
[
1445,
63,
1523
],
[
1523,
25,
455
]
],
[
[
1445,
24,
688
],
[
688,
63,
455
]
],
[
[
1445,
10,
11649
],
[
11649,... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol ma... |
DB00031 | DB00814 | 20 | 1,171 | [
"DDInter1764",
"DDInter1143"
] | Tenecteplase | Meloxicam | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
20,
24,
1171
]
],
[
[
20,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
20,
25,
936
],
[
936,
63,
1171
]
],
[
[
20,
24,
477
],
[
477,
63... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Tenecteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate dise... |
DB00323 | DB06691 | 1,062 | 849 | [
"DDInter1829",
"DDInter1155"
] | Tolcapone | Mepyramine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1062,
24,
849
]
],
[
[
1062,
24,
1594
],
[
1594,
24,
849
]
],
[
[
1062,
24,
407
],
[
407,
63,
849
]
],
[
[
1062,
63,
475
],
[
475,
... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cau... |
DB01611 | DB11718 | 1,487 | 927 | [
"DDInter893",
"DDInter640"
] | Hydroxychloroquine | Encorafenib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1487,
25,
927
]
],
[
[
1487,
63,
112
],
[
112,
23,
927
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
927
]
],
[
[
1487,
24,
720
],
[
720,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Su... |
DB00047 | DB00226 | 176 | 1,000 | [
"DDInter932",
"DDInter845"
] | Insulin glargine | Guanadrel | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Moderate | 1 | [
[
[
176,
24,
1000
]
],
[
[
176,
24,
22
],
[
22,
63,
1000
]
],
[
[
176,
24,
73
],
[
73,
24,
1000
]
],
[
[
176,
24,
22
],
[
22,
6,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine ... |
DB00059 | DB00218 | 1,560 | 1,176 | [
"DDInter1404",
"DDInter1247"
] | Pegaspargase | Moxifloxacin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Moderate | 1 | [
[
[
1560,
24,
1176
]
],
[
[
1560,
24,
37
],
[
37,
62,
1176
]
],
[
[
1560,
63,
816
],
[
816,
23,
1176
]
],
[
[
1560,
24,
549
],
[
549,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamic... |
DB00738 | DB09133 | 485 | 1,527 | [
"DDInter1420",
"DDInter965"
] | Pentamidine | Iothalamic acid | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
485,
25,
1527
]
],
[
[
485,
25,
762
],
[
762,
24,
1527
]
],
[
[
485,
64,
347
],
[
347,
24,
1527
]
],
[
[
485,
24,
116
],
[
116,
... | [
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u... | Pentamidine may lead to a major life threatening interaction when taken with Bepridil and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Pentamidine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide may cause a moderate int... |
DB00214 | DB00604 | 1,028 | 1,425 | [
"DDInter1836",
"DDInter385"
] | Torasemide | Cisapride | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
1028,
25,
1425
]
],
[
[
1028,
6,
10215
],
[
10215,
45,
1425
]
],
[
[
1028,
7,
2216
],
[
2216,
46,
1425
]
],
[
[
1028,
18,
2976
],
[
29... | [
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Cisapr... | Torasemide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Cisapride (Compound)
Torasemide (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Cisapride (Compound)
Torasemide (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Cisapride (Compound)
Torasemide may ca... |
DB01017 | DB11110 | 1,669 | 603 | [
"DDInter1224",
"DDInter1115"
] | Minocycline | Magnesium citrate | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1669,
24,
603
]
],
[
[
1669,
62,
863
],
[
863,
24,
603
]
],
[
[
1669,
23,
1326
],
[
1326,
24,
603
]
],
[
[
1669,
1,
1545
],
[
1545,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
],
... | Minocycline may cause a minor interaction that can limit clinical effects when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Minocycline may cause a minor interaction that can limit clinical effects when taken with Diclofenamide and ... |
DB00341 | DB01175 | 1,242 | 318 | [
"DDInter343",
"DDInter672"
] | Cetirizine | Escitalopram | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1242,
24,
318
]
],
[
[
1242,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1242,
6,
10104
],
[
10104,
45,
318
]
],
[
[
1242,
21,
29461
],
[
2946... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Cetirizine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Escitalopram (Compound)
Cetirizine (Compound) causes Dysmenorrhoea (Side Effect) and Dysme... |
DB00382 | DB00836 | 62 | 543 | [
"DDInter1734",
"DDInter1088"
] | Tacrine | Loperamide | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
62,
24,
543
]
],
[
[
62,
24,
262
],
[
262,
24,
543
]
],
[
[
62,
63,
701
],
[
701,
24,
543
]
],
[
[
62,
24,
1213
],
[
1213,
63,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Cl... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may... |
DB11796 | DB11986 | 1,612 | 484 | [
"DDInter786",
"DDInter648"
] | Fostemsavir | Entrectinib | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1612,
24,
484
]
],
[
[
1612,
62,
112
],
[
112,
23,
484
]
],
[
[
1612,
63,
774
],
[
774,
24,
484
]
],
[
[
1612,
23,
1320
],
[
1320,
... | [
[
[
"Fostemsavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and De... |
DB00902 | DB01278 | 104 | 1,021 | [
"DDInter1168",
"DDInter1506"
] | Methdilazine | Pramlintide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
104,
24,
1021
]
],
[
[
104,
24,
1680
],
[
1680,
24,
1021
]
],
[
[
104,
24,
1536
],
[
1536,
63,
1021
]
],
[
[
104,
63,
1507
],
[
1507,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Belladon... |
DB00697 | DB01176 | 876 | 537 | [
"DDInter1821",
"DDInter453"
] | Tizanidine | Cyclizine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
876,
24,
537
]
],
[
[
876,
63,
1242
],
[
1242,
24,
537
]
],
[
[
876,
24,
104
],
[
104,
1,
537
]
],
[
[
876,
21,
29054
],
[
29054,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methd... |
DB00794 | DB00990 | 759 | 1,547 | [
"DDInter1521",
"DDInter705"
] | Primidone | Exemestane | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Moderate | 1 | [
[
[
759,
24,
1547
]
],
[
[
759,
24,
891
],
[
891,
40,
1547
]
],
[
[
759,
63,
1573
],
[
1573,
40,
1547
]
],
[
[
759,
6,
8374
],
[
8374,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exemestane"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Exemestane (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Exemestane (Compound... |
DB00086 | DB08918 | 1,167 | 41 | [
"DDInter1712",
"DDInter1059"
] | Streptokinase | Levomilnacipran | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1167,
24,
41
]
],
[
[
1167,
24,
901
],
[
901,
40,
41
]
],
[
[
1167,
25,
498
],
[
498,
63,
41
]
],
[
[
1167,
25,
330
],
[
330,
24... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Streptokinase may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exace... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.